AngioDynamics Stock Forecast for 2023 - 2025 - 2030
Updated on 04/19/2024
AngioDynamics Stock Forecast and Price Target
The average target price for AngioDynamics's stock set by renowned analysts in recent months is $13.00, representing a potential upside of approximately 107.67% from its last closing price if met by 2025. This estimation is based on a high estimate of $18.00 and a low estimate of $10.00. If you're looking for AngioDynamics (ANGO) stock information, you might also want to check out Medtronic (NYSE:MDT).
107.67% Upside
AngioDynamics Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, AngioDynamics's Price has decreased by 100.00%, going from $3.70 to $0.00. Analysts predict that AngioDynamics's Fair Value will increase in the upcoming year, reaching $6.34. This would represent an increase of 100.00%. Over the next seven years, experts predict that AngioDynamics's Fair Value will grow at a rate of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| JNJ Stock Forecast | Johnson & Johnson | Outperform |
9
|
$147.91 | Buy/Sell | $174.55 | 14.93% |
| ABT Stock Forecast | Abbott Laboratories | Outperform |
9
|
$107.28 | Buy/Sell | $118.92 | 18.38% |
| SYK Stock Forecast | Stryker Corp | Outperform |
10
|
$325.43 | Buy/Sell | $353.16 | 12.62% |
| MDT Stock Forecast | Medtronic | Outperform |
11
|
$79.48 | Buy/Sell | $92.47 | 20.16% |
| BSX Stock Forecast | Boston Scientific | Outperform |
11
|
$67.33 | Buy/Sell | $70.14 | 8.42% |
AngioDynamics Revenue Forecast for 2023 - 2025 - 2030
In the last three years, AngioDynamics's Revenue has seen an increase, rising from $264.16M to $338.75M. This represents a growth of 28.24%. 4 analysts predict AngioDynamics's Revenue will decrease by 2.86% in the next year, reaching $329.05M. Over the next seven years, experts predict that AngioDynamics's Revenue will grow at a rate of 22.90%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BDX Stock Forecast | Becton Dickinson and Co | Outperform |
9
|
$234.12 | Buy/Sell | $284.47 | 19.60% |
| EW Stock Forecast | Edwards Lifesciences Corp | Outperform |
11
|
$85.94 | Buy/Sell | $91.18 | 12.87% |
| CAH Stock Forecast | Cardinal Health Inc | Hold |
13
|
$108.19 | Buy/Sell | $108.07 | 6.76% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 4543 Stock Forecast | Terumo | Outperform |
18
|
¥5.63k | Buy/Sell | ¥4.97k | -9.46% |
| BAX Stock Forecast | Baxter International Inc | Outperform |
17
|
$39.47 | Buy/Sell | $44.86 | 14.01% |
| SWAV Stock Forecast | Shockwave Medical | Hold |
4
|
$329.00 | Buy/Sell | $239.91 | 1.82% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| SN. Stock Forecast | Smith & Nephew | Outperform |
18
|
£9.62 | Buy/Sell | £16.09 | 70.58% |
| TFX Stock Forecast | Teleflex Inc | Hold |
13
|
$206.56 | Buy/Sell | $263.46 | 28.29% |
| GETI B Stock Forecast | Getinge AB | Outperform |
18
|
kr212.80 | Buy/Sell | kr226.10 | 5.73% |
AngioDynamics EBITDA Forecast for 2023 - 2025 - 2030
AngioDynamics's EBITDA has grown in the last three years, jumping from $9.77M to $12.19M – an increase of 24.77%. The next year, 1 experts forecast that AngioDynamics's EBITDA will decrease by 87.69%, reaching $1.50M. For the next seven years, the forecast is for EBITDA to grow by 209.81%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| AVAV Stock Forecast | AeroVironment | Outperform |
10
|
$150.02 | Buy/Sell | $125.75 | 19.98% |
| MMSI Stock Forecast | Merit Medical Systems | Outperform |
14
|
$72.03 | Buy/Sell | $89.25 | 22.87% |
| NARI Stock Forecast | Inari Medical | Outperform |
14
|
$38.59 | Buy/Sell | $82.67 | 81.39% |
AngioDynamics EBIT Forecast for 2023 - 2025 - 2030
In the last three years, AngioDynamics's EBIT has increased by 33.05%, going from $-14.04M to $-18.68M. According to the 2 analysts polled, in the next year, AngioDynamics's EBIT will fall by 12.69%, reaching $-16.31M. By 2030, professionals believe that AngioDynamics's EBIT will have decreased by 25.04%, falling to $-14.00M.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ULE Stock Forecast | Ultra Electronics Holdings | - |
16
|
£35.00 | Buy/Sell | £29.25 | -100.00% |
| IART Stock Forecast | Integra LifeSciences Holdings | Hold |
16
|
$28.68 | Buy/Sell | $46.60 | 51.67% |
| 1066 Stock Forecast | Shandong Weigao Group Medical ... | Outperform |
16
|
HK$4.76 | Buy/Sell | HK$11.68 | 52.52% |
AngioDynamics EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, AngioDynamics's EPS has decreased by 100.00%, going from $0.09 to $0.00. Analysts predict that AngioDynamics's EPS will increase in the upcoming year, reaching $-0.32. This would represent an increase of 100.00%. Over the next seven years, experts predict that AngioDynamics's EPS will grow at a rate of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| PLXS Stock Forecast | Plexus | Outperform |
16
|
$93.24 | Buy/Sell | $108.00 | 15.78% |
| CNMD Stock Forecast | CONMED | Outperform |
16
|
$72.64 | Buy/Sell | $123.38 | 47.99% |
| RAVN Stock Forecast | Raven Industries | - |
18
|
$58.08 | Buy/Sell | $58.00 | -100.00% |
.jpg)